Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod 0.5 mg in Relapsing Multiple Sclerosis (China, Pediatric and Adult, Phase IV)
CTR20202524Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Started Dec 2020; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20202524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202524.